JAK2 inhibitors for myeloproliferative neoplasms: what is next? von Bose, Prithviraj, Verstovsek, Srdan

Volltext

Therapeutic potential of JAK2 inhibitors von Verstovsek, Srdan

Volltext

Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance von QUINTAS-CARDAMA, Alfonso, VERSTOVSEK, Srdan

Volltext

Paradigm shift: combination BET and JAK inhibition in myelofibrosis von Mascarenhas, John, Gerds, Aaron, Verstovsek, Srdan

Volltext

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera von Vannucchi, Alessandro M, Kiladjian, Jean Jacques, Griesshammer, Martin, Masszi, Tamas, Durrant, Simon, Passamonti, Francesco, Harrison, Claire N, Pane, Fabrizio, Zachee, Pierre, Mesa, Ruben, He, Shui, Jones, Mark M, Garrett, William, Li, Jingjin, Pirron, Ulrich, Habr, Dany, Verstovsek, Srdan

Volltext

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis von Verstovsek, Srdan, Mesa, Ruben A, Gotlib, Jason, Levy, Richard S, Gupta, Vikas, DiPersio, John F, Catalano, John V, Deininger, Michael, Miller, Carole, Silver, Richard T, Talpaz, Moshe, Winton, Elliott F, Harvey, Jimmie H, Arcasoy, Murat O, Hexner, Elizabeth, Lyons, Roger M, Paquette, Ronald, Raza, Azra, Vaddi, Kris, Erickson-Viitanen, Susan, Koumenis, Iphigenia L, Sun, William, Sandor, Victor, Kantarjian, Hagop M

Volltext

Momelotinib: an emerging treatment for myelofibrosis patients with anemia von Chifotides, Helen T, Bose, Prithviraj, Verstovsek, Srdan

Volltext

The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes von Mascarenhas, John O., Verstovsek, Srdan

Volltext

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives von Bose, Prithviraj, Verstovsek, Srdan

Volltext

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet von Barbui, Tiziano, Tefferi, Ayalew, Vannucchi, Alessandro M., Passamonti, Francesco, Silver, Richard T., Hoffman, Ronald, Verstovsek, Srdan, Mesa, Ruben, Kiladjian, Jean-Jacques, Hehlmann, Rȕdiger, Reiter, Andreas, Cervantes, Francisco, Harrison, Claire, Mc Mullin, Mary Frances, Hasselbalch, Hans Carl, Koschmieder, Steffen, Marchetti, Monia, Bacigalupo, Andrea, Finazzi, Guido, Kroeger, Nicolaus, Griesshammer, Martin, Birgegard, Gunnar, Barosi, Giovanni

Volltext

Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval von Verstovsek, Srdan, Parasuraman, Shreekant, Yu, Jingbo, Shah, Anne, Kumar, Shambhavi, Xi, Ann, Harrison, Claire

Volltext

Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation von Newberry, Kate J., Patel, Keyur, Masarova, Lucia, Luthra, Rajyalakshmi, Manshouri, Taghi, Jabbour, Elias, Bose, Prithviraj, Daver, Naval, Cortes, Jorge, Kantarjian, Hagop, Verstovsek, Srdan

Volltext

Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond von Quintás-Cardama, Alfonso, Kantarjian, Hagop, Cortes, Jorge, Verstovsek, Srdan

Volltext

Mutational profiling in myelofibrosis: implications for management von Bose, Prithviraj, Verstovsek, Srdan

Volltext

Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial von DeAngelo, Daniel J., Radia, Deepti H., George, Tracy I., Robinson, William A., Quiery, Albert T., Drummond, Mark W., Bose, Prithviraj, Hexner, Elizabeth O., Winton, Elliott F., Horny, Hans-Peter, Tugnait, Meera, Schmidt-Kittler, Oleg, Evans, Erica K., Lin, Hui-Min, Mar, Brenton G., Verstovsek, Srdan, Deininger, Michael W., Gotlib, Jason

Volltext

Potential limitations of diagnostic standard codes to distinguish polycythemia vera and secondary erythrocytosis von Barrios-Ruiz, Alanna, Davila-Gonzalez, Daniel, Fountain, Eric, Cheng, Lee, Verstovsek, Srdan, Rojas-Hernandez, Cristhiam M.

Volltext

Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies von Zahr, Abdallah Abou, Salama, Mohamed E, Carreau, Nicole, Tremblay, Douglas, Verstovsek, Srdan, Mesa, Ruben, Hoffman, Ronald, Mascarenhas, John

Volltext

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis von Verstovsek, Srdan, Kantarjian, Hagop, Mesa, Ruben A, Pardanani, Animesh D, Cortes-Franco, Jorge, Thomas, Deborah A, Estrov, Zeev, Fridman, Jordan S, Bradley, Edward C, Erickson-Viitanen, Susan, Vaddi, Kris, Levy, Richard, Tefferi, Ayalew

Volltext

Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus repo... von Tefferi, Ayalew, Cervantes, Francisco, Mesa, Ruben, Passamonti, Francesco, Verstovsek, Srdan, Vannucchi, Alessandro M., Gotlib, Jason, Dupriez, Brigitte, Pardanani, Animesh, Harrison, Claire, Hoffman, Ronald, Gisslinger, Heinz, Kröger, Nicolaus, Thiele, Juergen, Barbui, Tiziano, Barosi, Giovanni

Volltext

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses von Verstovsek, Srdan, Gotlib, Jason, Mesa, Ruben A, Vannucchi, Alessandro M, Kiladjian, Jean-Jacques, Cervantes, Francisco, Harrison, Claire N, Paquette, Ronald, Sun, William, Naim, Ahmad, Langmuir, Peter, Dong, Tuochuan, Gopalakrishna, Prashanth, Gupta, Vikas

Volltext